By Kyle Morris

Shares in Polarean Imaging PLC rose 20% on Thursday after the company said that it had filed the resubmission of its new drug application for its hyperpolarized Xenon gas drug-device combination product with the Food and Drug Administration.

The medical-imaging technology company said previous issues raised by the FDA have now been addressed and it is expected that the FDA review period will take six months.

Shares in Polarean Imaging at 0855 GMT were up 10.50 pence at 62.50 pence.

Write to Kyle Morris at kyle.morris@dowjones.com

(END) Dow Jones Newswires

March 31, 2022 04:27 ET (08:27 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Polarean Imaging Charts.
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Polarean Imaging Charts.